Press Releases

Imprime PGG-MAb Combination Therapy Achieves High Response Rate in Patients with Chronic Lymphocytic Leukemia

CHICAGO — May 31, 2015 — A combination of Biothera’s Imprime PGG and the monoclonal antibodies alemtuzumab and rituximab achieved responses in 13 of 14 (93%) patients with high-risk chronic lymphocytic leukemia, including nine (64%) complete responses. Results of this phase 1/2 study will be presented today at the American Society of Clinical Oncology (ASCO). Imprime PGG is an investigational cancer immunotherapy that directly modulates...

Read More


Integrated Safety Data from Two Phase 2 Cancer Studies Demonstrates Biothera’s Investigational Cancer Immunotherapy is Well Tolerated

CHICAGO — May 31, 2015 — A new, combined analysis of patient-level data from two randomized studies in non-small cell lung cancer provides further evidence that Biothera’s investigational immunotherapy Imprime PGG is safe and well tolerated, with adverse events generally consistent with complications of the disease and toxicities attributable to the cytotoxic drugs or monoclonal antibody therapies. Biothera presented the data yesterday at the American...

Read More


Biothera Presents Additional Data at ASCO on Durability and Characteristics of Response with Imprime PGG in Non-Small Cell Lung Cancer Study

CHICAGO — May 31, 2015 — Biothera’s investigational cancer immunotherapy Imprime PGG in combination with standard platinum-based doublet chemotherapy and the monoclonal antibody bevacizumab achieved rapid and lasting responses in patients with non-squamous non-small cell lung cancer (NSCLC). Tumor reduction was observed regardless of tumor burden (up to > 30 cm) or location of lesions at baseline (including lung, lymph nodes, adrenals, liver). These findings...

Read More


Biothera to Present New Data at the American Society of Clinical Oncology Annual Meeting

EAGAN, MN — May 28, 2015 — Biothera announced today that new data and insights for Imprime PGG, the company’s investigational cancer immunotherapy drug, will be featured in four presentations at the 2015 American Society of Clinical Oncology annual meeting May 29-June 2 in Chicago. Saturday, May 30; 8:00 am-11:30 am. Location: S Hall A: Abstract #3070. Poster Board Number #396Durability and Characteristics of Objective...

Read More


Biothera to Present Additional Data to the American Association of Immunologists on Imprime PGG’s Potential to Alleviate Tumor-mediated Immunosuppression

NEW ORLEANS — May 8, 2015 — Additional data showing Biothera’s investigational cancer immunotherapy Imprime PGG can alleviate tumor-mediated immunosuppression and potentially strengthen the body’s ability to recognize and kill tumor cells will be presented on Sunday at the American Association of Immunologists (AAI) annual meeting. Earlier this month at the American Association for Cancer Research, Biothera presented new research supporting the potential of Imprime...

Read More


Biothera’s Investigational Cancer Immunotherapy Alleviates Immune Suppression by Regulatory T Cells, Enabling CD4 and CD8 T Cell Proliferation, Study Finds

New Data Presented at the American Association for Cancer Research Annual Meeting PHILADELPHIA — April 22, 2015 — Biothera’s investigational cancer immunotherapy Imprime PGG enhances the function and proliferation of T cells that play a critical role in the fight against cancer, according to new data presented today at the American Association for Cancer Research (AACR) annual meeting. “Cancer can create an immunosuppressive environment that...

Read More


New Data Demonstrate Potential of Biothera’s Investigational Cancer Immunotherapy to Re-orient the Tumor Microenvironment to Facilitate Greater Anti-Tumor Activity

Company to Present Four Scientific Posters at the American Association for Cancer Research Annual Meeting PHILADELPHIA – April 21, 2015 – Biothera is presenting new data today at the world’s largest meeting of cancer researchers that shows its investigational cancer immunotherapy drug Imprime PGG has the potential to initiate a coordinated anti-tumor response involving both the innate and adaptive immune systems. “Cancer often creates a...

Read More


Biothera’s Investigational Cancer Immunotherapy Drug Imprime PGG Elicits Dramatic Expansion of Cytotoxic T Cells

Late-Breaking Data Presented at the American Association for Cancer Research (AACR) Annual Meeting PHILADELPHIA – April 21, 2015 – Biothera researchers are presenting several studies at this year’s AACR meeting showing that treatment with its investigational immunotherapy Imprime PGG consistently triggers expansion of cytotoxic T cells (CD8+ T cells)—cells critically responsible for eradicating virally infected cells and for selectively killing cancer cells. A late-breaking research...

Read More


Biothera’s Imprime PGG Cancer Immunotherapy Drug Candidate Shows Potential to Enhance Efficacy of Immune Checkpoint Inhibitors

New Data on Imprime PGG’s Ability to Enhance Expression of PD-L1 on Tumor Cells Presented at the American Association for Cancer Research Annual Meeting PHILADELPHIA – April 21, 2015 – A scientific poster presented today during a late-breaking session at the American Association for Cancer Research (AACR) annual meeting showed that Biothera’s Imprime PGG investigational cancer immunotherapy may have the potential to enhance the efficacy...

Read More


Biothera’s Imprime PGG Investigational Immunotherapy Drug Modulates the Function of Macrophages and Dendritic Cells to Drive Expansion of Anti-cancer T Cells

Study Further Supports the Role of Imprime PGG in Triggering a Coordinated Immune Response PHILADELPHIA – April 21, 2015 – New research demonstrates that Imprime PGG, an investigational cancer immunotherapy drug in late-stage development by Biothera, modulates the function of key cells of the innate immune system—macrophages and dendritic cells—to drive expansion of T cells, which are critical for anti-cancer immunity. The results were reported...

Read More



Page 5 of 6« First...23456